PPH
VanEck Pharmaceutical ETF·Financial Services
103.83
1.011%(−1.06)
Market ClosedLast Updated: — ET
52W L: $81.7452W H: $112.58
PPH NEWS
zacks.com
Apr 2
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
247wallst.com
Mar 28
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline.
defenseworld.net
Feb 23
Avalon Trust Co Has $24.89 Million Position in VanEck Pharmaceutical ETF $PPH
Avalon Trust Co lessened its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 1.8% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 275,400 shares of the company's stock after selling 5,077 shares during the quarter. VanEck Pharmaceutical ETF makes
zacks.com
Jan 28
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
defenseworld.net
Jan 28
VanEck Pharmaceutical ETF $PPH Shares Sold by Adamsbrown Wealth Consultants LLC
Adamsbrown Wealth Consultants LLC lowered its position in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 30.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,899 shares of the company's stock after selling 59,077 shares during the quarter. VanEck Pharmaceutical
247wallst.com
Jan 23
VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund's concentrated bet on GLP-1 manufacturers makes this a call option on the market's continued growth. Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) combined represented nearly one-third of the ETF. If you believe the... VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion.
